Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection

Completed · Phase 2

Conditions studied: Hepatitis B, Chronic

In brief

This is a phase 2 study in which participants with chronic hepatitis B virus (HBV) infection will receive VIR-2218, VIR-3434 and/or PEG-IFNα and be assessed for safety, tolerability, and efficacy

Key facts

Study ID

NCT04856085

Run by

Vir Biotechnology, Inc.

People needed

244

Starts

2021-07-11

Expected to finish

2026-03-16

Last updated by the study team

2026-04-23

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female ages 18 - <66 years
• Chronic HBV infection for >/= 6 months
• On NRTI therapy for >/= 2 months at the time of screening

You may not qualify if…

• Any clinically significant chronic or acute medical condition that makes the participant unsuitable for participation
• Significant fibrosis or cirrhosis
• History or evidence of drug or alcohol abuse
• History of chronic liver disease from any cause other than chronic HBV infection
• History of hepatic decompensation
• History of anaphylaxis
• History of allergic reactions, hypersensitivity, or intolerance to monoclonal antibodies, antibody fragments, or any excipients of VIR-3434
• History of immune complex disease
• History of known contraindication to any interferon product

Where it is running

• Investigative Site — San Francisco, California, United States
• Investigative Site — Miami, Florida, United States
• Investigative Site — Orlando, Florida, United States
• Investigative Site — Baltimore, Maryland, United States
• Investigative Site — Hillsborough, New Jersey, United States
• Investigative Site — Toronto, Canada
• Investigative Site — Toronto, Canada
• Investigative Site — Vancouver, Canada
• Investigative Site — Frankfurt, Germany
• Investigative Site — Hanover, Germany
• Investigative Site — Mannheim, Germany
• Investigative Site — Hong Kong, Shatin, Hong Kong
• Investigative Site — Hong Kong, Tai Po District, Hong Kong
• Investigative Site — Hong Kong, Hong Kong
• Investigative Site — Kuala Lumpur, Malaysia
• Investigative Site — Chisinau, Moldova
• Investigative Site — Auckland, New Zealand
• Investigative Site — Auckland, New Zealand
• Investigative Site — Hamilton, New Zealand
• Investigative Site — Tauranga, New Zealand
• Investigative Site — Wellington, New Zealand
• Investigative Site — Bucharest, Romania
• Investigative Site — Busan, South Korea
• Investigative Site — Seoul, South Korea
• Investigative Site — Seoul, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.